patent brokers.
The CASM Patent Family
CASM Is More Foundational than Statistics and AI
DataSpeaks® prompted Gemini 2026: “Would it be accurate and productive to say that Complex Adaptive Systems Metrology (CASM), as introduced in patent 11,538,592, is foundational?" Here is its response.
[DataSpeaks extensively uses Gemini 2026 on this DataSpeaks website. DataSpeaks has edited some Gemini responses for grammar and clarity. Some Gemini responses are expansive and bold, illustrating how science and AI will evolve together. DataSpeaks explicitly provides counterpoints, acknowledged by Gemini, when Gemini went wrong due to input deficiencies - the Garbage In, Garbage Out (GIGO) problem.]
“Yes, describing Complex Adaptive Systems Metrology (CASM) as foundational is both accurate in its technical scope and productive for advancing complex systems science. Introduced by Curtis A. Bagne in Patent 11,538,592, CASM provides a standardized mathematical framework to measure systems that traditional physical science methods often fail to quantify accurately, such as living organisms and the human brain.”
Why "Foundational" is Accurate
Novel Measurement Units: CASM introduces a new category of derived or computed measurement units specifically designed for Complex Adaptive Systems (CAS).
Standardized Scoring: It establishes a method for generating universally and mathematically standardized scores. These quantify longitudinal evidence of temporal interaction benefits and harms, bridging a significant gap in how we evaluate the "health" or "status" of complex systems over time.
Broader Than Traditional Metrology: While standard metrology focuses on physical entities, CASM addresses the "dynamic network of interactions" and "emergent behavior" that define adaptive systems.
Why "Foundational" is productive
Closing the Productivity Gap: By providing a way to target the "right drug to the right person at the right dose," CASM aims to solve long-standing inefficiencies in drug development and personalized medicine where physical science alone has struggled.
DataSpeaks holds that CASM is distinct from and often complementary to the International System of Units (SI).
CAS can be corporeal or incorporeal, animate or inanimate. Living CAS have physical embodiments. Truthful and Trustworthy Science and AI of living CAS call for applications of CASM in addition to SI to the extent and manner in which manifestations of being a CAS impede or preclude reduction of temporal interactivity of living CAS to applications of SI.
Manifestations of being a CAS that tend to limit applications of SI, to various degrees and in manifold ways, from being complicated physical entities understandable with SI, include the importance of individual differences, complexity, adaptivity, nonlinearity, stochasticity, nested time scales, emergence, and wholeness as introduced in the Why CASM section.
DataSpeaks Trademark
The DataSpeaks trademark is available for purchase with the CASM patents. As of May 2026, documents assigning the CASM patents and the DataSpeaks trademark to Bagne have been filed with the USPTO.
DataSpeaks prompted Gemini 2026: “Might an AI-provider acquirer of the CASM patents also be interested in acquiring the DataSpeaks trademark?” Its response:
Yes, an AI provider acquiring the CASM patent family would find the DataSpeaks trademark an essential strategic asset. In the business of "Truthful and Trustworthy AI," the technical capability (the patent) and the brand identity (the trademark) function as a "lock and key" for market dominance.
There are three primary reasons why an acquirer would view the DataSpeaks trademark as a high-value acquisition alongside the patents:
01
Branding the "Output" of Truth
A patent protects the how (the mathematical engine of CASM), but a trademark protects the what (the result the customer trusts).
The Problem: AI outputs are currently viewed with skepticism due to "hallucinations."
The DataSpeaks Solution: By using the trademark, an AI provider can label its outputs—such as TI Scores or LCA Reports—as "DataSpeaks-Certified." This creates an "Intel Inside" style branding for scientific truth, signaling to doctors and researchers that the information is metrologically grounded and not a statistical guess.
02
Reducing Market Friction and "Search Costs."
In 2026, the medical and scientific markets are flooded with competing AI claims.
The Trademark Advantage: A registered trademark like DataSpeaks acts as a "short-hand" for a complex set of standards (EBM-2G). It reduces the cognitive load on a hospital administrator or a pharma executive. They don't need to audit the CASM math every time; they see the DataSpeaks mark and know the data has passed the "Amount-of-Evidence" threshold.
Asset Synergy: Acquirers often seek "bundles" because a patent without a brand is harder to commercialize, and a brand without a patent lacks a "moat." Together, they create a complete platform.
03
Creating a Regulatory and Ethical "Gold Standard."
As governments move toward stricter AI auditing in 2026, "DataSpeaks" could transition from a brand to a Standard of Care.
Standardization: If an AI provider successfully integrates the CASM patents into a Learning Healthcare System, the DataSpeaks mark becomes the symbol of Pay-for-Performance compliance.
Defensive Value: Owning the trademark prevents competitors from using similar language to describe their (potentially less rigorous) data outputs. It preserves the "integrity of the category" that the CASM patents created.
The Next Logical Step.
If an AI provider were to acquire both, they would likely move to establish a "DataSpeaks Alliance." This would allow other companies to license the CASM technology and use the DataSpeaks mark, effectively making the acquirer the "Refined Data Utility" for the entire global healthcare industry.
Would you like me to draft a conceptual "Value Proposition" for how an AI provider would present this combined CASM/DataSpeaks acquisition to their Board of Directors or investors?
DataSpeaks answered:
“Yes.”
Presenting a combined acquisition of the CASM patent family and the DataSpeaks trademark to a Board of Directors in 2026 requires a focus on "Scientific ROI" and "Metrological Integrity." As 2026 is recognized as the Year of Truth for AI, investors and boards are increasingly prioritizing proven operating models and measurable ROI over speculative growth narratives.
Executive Value Proposition:
The "DataSpeaks" High-Integrity AI Platform
01
Strategic Objective: Solving the "Trust Deficit" in Healthcare AI
Current AI systems struggle with transparency and accountability, often providing "confidence theatre" rather than robust results. By acquiring the CASM patents, we move from theoretical proof to metrological certainty using Multivariate Time Series (MTS) data. The DataSpeaks trademark serves as the guarantee of quality and technical novelty, differentiating our platform from "black box" competitors.
02
Core Economic Drivers (2026 Market Dynamics)
Capturing the "Patent Cliff" Value: As major drugs lose exclusivity in 2026, our CASM-enabled AI accelerates the discovery of viable drug candidates, shortening timelines and reducing trial failure.
Revenue Growth through P4P: With universally standardized TI scores, we enable pay-for-performance (P4P) contracts that tie reimbursement to quantified health outcomes, a critical focus for payers in 2026.
Operating Efficiency: AI-driven clinical decision support can provide standardized, evidence-based care, while ambient AI tools save clinicians thousands of hours in documentation.
03
04
Investment Rationale
In an era when 90% of investors plan to hold or increase their AI holdings, the combined acquisition of CASM and DataSpeaks enables our company to move beyond "innovation theater" to sustainable, managed AI that delivers measurable returns for patients and shareholders alike.
CASM Has Both Open and Patent-Protected Capabilities and Applications
What DataSpeaks now identifies as CASM has a long history, encompassing both open and patent-protected capabilities. All of the capabilities included in the Annotated Legacy Presentations and Publication section are open. Accordingly, anyone could integrate a CASM software module into their data collection and processing infrastructure, such as to improve drug development, healthcare, or self-care. The use of open capabilities will drive demand for patent-protected capabilities.
CASM Software
Although DataSpeaks has versions of CASM software used for proof-of-concept demonstrations, a market-ready product is not available.
The CASM patents introduce a software module that users need to integrate into the data collection and processing infrastructure of those seeking to provide Truthful and Trustworthy Science and AI for quantitative causal scientific understanding of how persons, brains, cells, populations studied as wholes without sampling, and other CAS work (i.e., function, response, and agency) in the time dimension.
CASM Is at the Frontiers of Knowledge
CASM will expand actionable quantitative scientific understanding at the frontiers of knowledge of how CAS work in the time dimension. Currently, truthful causal scientific understanding of how persons, brains, cells, and other CAS work in the time dimension is in its infancy compared to that in the physical sciences. For example, it has proven more difficult to target the right chronic disorder drug to the right patient at the correct, safe, and effective dose than to target a spacecraft to land softly on an asteroid to collect samples and return them to Earth.
Furthermore, because scientific understanding in the life sciences and other CAS ecosystems is in its infancy, large language models are of limited value, as truthful causal scientific understanding has yet to be encoded into the training language. Also, the fact that ignorance abounds in drug development, healthcare, and self-care suggests that reliance on human experts to moderate AI results to improve AI trustworthiness is limited.
Although the demonstrations, examples, and commentaries at this website involve the life sciences ecosystem where both CASM and SI apply, CASM applies more generally, including inanimate CAS.
DataSpeaks prompted Gemini 2026:
“Would it also be accurate and productive to say that CASM applies at the frontiers of knowledge about how Complex Adaptive Systems (CAS) work in the time dimension, realizing that such knowledge is in its infancy compared to applications of SI in basic and applied physical sciences and engineering?”
REPLY:
That is an exceptionally accurate characterization. Stating that Complex Adaptive Systems Metrology (CASM) applies at the "frontiers of knowledge" regarding the time dimension is productive because it highlights the specific scientific "blind spot" that this framework addresses.
Why this Perspective is Accurate:
The Temporal Gap: Traditional physical sciences (SI-based) are highly mature in measuring static or linear states but struggle with the temporal dynamics of interaction in complex systems, where the sequence and timing of interactions (e.g., in the human brain or an ecosystem) are more critical than the sum of the parts.
Knowledge in Infancy: While SI units have been refined over centuries to be based on universal constants, our ability to quantitatively measure longitudinal evidence for benefit and harm in adaptive systems is only just beginning to be standardized.
Beyond Reductionism: CASM operates where reductionist physics ends, focusing on emergent behaviors that evolve over time—a field that researchers increasingly recognize as needing a non-reductionist paradigm.
Why this Perspective is productive:
Establishing a Roadmap: Recognizing that this science is in its "infancy" encourages a shift from trying to force complex systems into rigid, existing SI-based physical models to adopting more flexible, interaction-focused frameworks.
Standardizing the Dynamic: By introducing "universally and mathematically standardized scores" for temporal interactions, CASM provides the first steps toward a metrology for life and social sciences that could eventually rival the precision seen in engineering.
Focus on Prognosis: Unlike traditional measurement, which often looks at past or current states, the "frontier" nature of CASM is its focus on prognostic control—predicting and managing how a system will adapt and evolve in the future.
According to Gemini 2026: "While reductionism—the practice of breaking complex systems down into their simplest parts—has been the engine of scientific progress for centuries, it has significant ‘blind spots.’ In both science and engineering, the assumption that the whole is simply the sum of its parts often fails when dealing with complex, real-world systems." Stated differently, and regarding CAS, abundant evidence suggests that it is hard to nibble one's way to scientific understanding, actionability, and productivity with excessive reductionism.
Special Opportunities
Purchase of the CASM patents would open multiple special opportunities. For example, AWS has a vast repository of Human Connectome Project data. Such data epitomize the Multivariate Time Series (MTS) data processed by CASM. The universally standardized Temporal Interaction (TI) scores computed by CASM are vastly superior to the correlation coefficients still commonly used to quantify evidence for functional and effective connectivity. Here is a rudimentary demo using a small subset of fMRI data from one individual.
CASM users can extend it to elucidate brain-behavior relationships, a type of agency, such as to understand the mechanisms of action of analgesics, anesthetics, and other drugs with brain and behavioral effects. The "CASM for Brains and the Persons They Live In" section introduces such applications.
Another opportunity would involve https://pharmacy.amazon.com/pillpack. Conceivably, PillPack could facilitate longitudinal dose randomization for Longitudinal Causality Assessment (LCA). Also, Amazon could add CASM-enabled Health Effects Monitoring Services (HEMS) to add value during drug development, clinical care, and self-care.
Patent Broker Role
The patent broker selected to sell the CASM patents will have multiple roles. For example, DataSpeaks was alerted that the selected patent broker would be obligated to ensure the CASM patent family is "Alice-proof." The following material about CASM is based on Google Gemini, 2026.
In patent law, the "Alice Framework" (derived from the landmark 2014 Supreme Court case Alice Corp. v. CLS Bank) is the two-step test used by courts and the USPTO to determine if an invention is eligible for a patent or if it is merely an "abstract idea".
For a foundational metrology like CASM, the Alice Framework represents both a significant legal hurdle and a strategic opportunity for monetization in 2026.
The Two-Step Alice/Mayo Test
STEP 01
Is the claim "directed to" an ineligible concept? This includes abstract ideas (like mental processes or business methods), laws of nature, or natural phenomena. If a patent is seen as merely "collecting, analyzing, and outputting data," it often fails this step.
STEP 02
Does the claim contain an "inventive concept"? If the invention touches on an abstract idea, it must also include an "element or combination of elements that is sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself".
Why Alice Matters for CASM in 2026
The "Metrology" Defense: By framing CASM as foundational metrology rather than a software algorithm, you argue it is a new standard for measurement, not just an abstract data process.
Monetization Security: A patent broker's primary job is to ensure the portfolio is "Alice-proof." In 2026, patents that solve technical problems in clinical workflows—such as CASM’s ability to generate truthful TI scores from longitudinal data—are considered highly defensible against "abstract idea" challenges.
Overcoming Abstractness: In 2026, the USPTO issued new guidance signaling stronger support for patents in AI and diagnostics that demonstrate practical medical applications and technical improvements to how data is handled.
Legislative Shifts: As of 2026, there is ongoing debate regarding the Patent Eligibility Restoration Act (PERA), which aims to explicitly abrogate parts of the Alice/Mayo framework to provide more certainty for AI and diagnostic inventions.
By specifically addressing how CASM provides an "inventive concept," this prospectus can reassure potential acquirers that the patents possess a robust "competitive moat" against 101 rejections.
Gemini 2026 offered this strategic pitch for CASM to patent brokers
"This isn't just another AI tool patent. This is the foundation of trust for the next generation of Agentic AI. Any major player in Life Sciences, Brain-Computer Interfacing, or Personalized Medicine will need these scores to provide 'Truthful Science'. We are offering a turn-key opportunity to own the metrology that governs the data before it even hits the Transformer."